Sino Biopharmaceutical revenue and financials
In the fiscal year ended December 2025, Sino Biopharmaceutical reported revenue of ¥31.83B (+10.28% year over year). Net income was ¥2.34B, a net margin of 7.4%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +10.28%
- 2025 vs 2024
- Net income growth
- −33.04%
- 2025 vs 2024
- Net margin
- 7.4%
- 2024: 12.1%
How Sino Biopharmaceutical is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 6.1% a year on average over the last 5 years
Compound annual growth rate: from ¥23.65B in 2020 to ¥31.83B in 2025.
Revenue has grown for 3 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Shares outstanding down 4.0% in 5 years
Average diluted shares, 2020 → 2025: with fewer shares, each one represents a larger stake in the company.
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 31,834 | 28,866 | 26,199 | 26,026 | 26,861 | 23,647 | 24,234 | 20,889 | 14,819 | 13,543 |
| Cost of revenue | 5,708 | 5,336 | 4,990 | 4,488 | 5,332 | 5,182 | 4,926 | 4,197 | 3,091 | 2,817 |
| Gross profit | 26,127 | 23,530 | 21,210 | 21,539 | 21,529 | 18,465 | 19,308 | 16,692 | 11,729 | 10,727 |
| Selling, general and administrative | 13,137 | 12,159 | 11,067 | 11,709 | 12,704 | 11,629 | 11,797 | 10,268 | 6,905 | 6,493 |
| Research and development | 5,866 | 5,089 | 4,403 | 4,164 | — | — | — | — | — | — |
| Operating income | 6,291 | 5,801 | 5,439 | 5,386 | 4,633 | 4,098 | 4,953 | 4,121 | 3,222 | 2,708 |
| EBIT | 6,291 | 5,801 | 5,439 | 5,386 | 4,633 | 4,098 | 4,953 | 4,121 | 3,222 | 2,708 |
| EBITDA | 7,255 | 6,893 | 6,379 | 6,254 | 5,453 | 5,661 | 6,275 | 5,281 | 3,561 | 3,021 |
| Interest expense | 278 | 295 | 495 | 429 | 309 | 323 | 230 | 153 | 77.9 | 76.6 |
| Pre-tax income | 6,943 | 5,277 | 5,410 | 5,215 | 18,573 | 5,013 | 5,691 | 11,429 | 4,196 | 3,203 |
| Income tax | 1,629 | 493 | 797 | 697 | 1,958 | 672 | 903 | 696 | 542 | 475 |
| Net income | 2,343 | 3,500 | 2,332 | 2,544 | 14,608 | 2,771 | 2,762 | 9,046 | 2,171 | 1,637 |
| Net income to common shareholders | 2,343 | 1,920 | 1,847 | 2,059 | 14,608 | 2,771 | 2,762 | 9,046 | 2,171 | 1,637 |
| Basic EPS | 0.13 | 0.10 | 0.10 | 0.11 | 0.78 | 0.15 | 0.15 | 0.49 | 0.13 | 0.10 |
| Diluted EPS | 0.13 | 0.10 | 0.10 | 0.10 | 0.73 | 0.15 | 0.15 | 0.49 | 0.13 | 0.10 |
| Average shares (basic) | 18,002 | 18,294 | 18,529 | 18,622 | 18,769 | 18,800 | 18,811 | 18,549 | 16,677 | 16,677 |
| Average shares (diluted) | 18,057 | 18,295 | 18,529 | 19,017 | 19,283 | 18,800 | 18,811 | 18,549 | 16,677 | 16,677 |
| Dividend per share | 0.09 | 0.07 | 0.04 | 0.11 | 0.07 | 0.06 | 0.05 | 0.05 | 0.03 | 0.02 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 19,444 | 14,260 | 17,575 | — | 15,874 | — | 14,284 | — | 15,194 | 12,508 |
| Cost of revenue | 3,297 | 2,627 | 3,081 | — | 2,845 | — | 2,600 | — | 2,960 | 2,579 |
| Gross profit | 16,148 | 11,633 | 14,494 | — | 13,030 | — | 11,684 | — | 12,234 | 9,929 |
| Selling, general and administrative | 6,230 | 5,593 | 7,543 | — | 6,848 | — | 6,226 | — | 6,934 | 5,912 |
| Research and development | 3,080 | 5,866 | 3,188 | — | — | — | — | — | — | — |
| Operating income | 6,612 | 2,883 | 3,408 | — | 3,470 | — | 3,039 | — | 3,161 | 1,611 |
| EBIT | 6,612 | 2,883 | 3,408 | — | 3,470 | — | 3,039 | — | 3,161 | 1,611 |
| EBITDA | 7,131 | 3,317 | 3,938 | — | 3,951 | — | 3,629 | — | 3,537 | 2,033 |
| Interest expense | 170 | 155 | 123 | — | 154 | — | 293 | — | 169 | 161 |
| Pre-tax income | 7,339 | 976 | 5,967 | — | 3,614 | — | 3,054 | — | 3,755 | 7,594 |
| Income tax | 1,196 | 648 | 981 | — | 614 | — | 498 | — | 571 | 621 |
| Net income | 3,435 | -1,045 | 3,389 | — | 3,017 | — | 1,259 | — | 1,921 | 6,128 |
| Net income to common shareholders | 3,435 | -1,045 | 3,389 | — | 3,017 | — | 1,259 | — | 1,921 | 6,128 |
| Basic EPS | 0.19 | -0.06 | 0.19 | — | 0.16 | — | 0.07 | — | 0.10 | 0.33 |
| Diluted EPS | 0.19 | -0.06 | 0.19 | — | 0.16 | — | 0.07 | — | 0.09 | 0.30 |
| Average shares (basic) | 17,983 | 18,001 | 18,004 | — | 18,408 | — | 18,564 | — | 18,659 | 18,756 |
| Average shares (diluted) | 18,050 | 18,088 | 18,026 | — | 18,410 | — | 18,564 | — | 19,123 | 19,277 |
| Dividend per share | 0.06 | 0.04 | 0.05 | — | 0.03 | — | 0.02 | — | 0.05 | 0.03 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 76,010 | 65,408 | 63,605 | 64,064 | 60,543 | 47,210 | 37,514 | 49,780 | 20,935 | 18,384 |
| Current assets | 34,465 | 24,685 | 23,806 | 25,935 | 23,503 | 22,794 | 24,913 | 18,538 | 13,780 | 12,732 |
| Cash and equivalents | 12,181 | 9,570 | 9,452 | 12,066 | 10,569 | 11,259 | 11,911 | 6,676 | 4,188 | 3,766 |
| Short-term investments | 415 | 221 | 1,553 | 4,855 | 570 | 956 | 5,618 | 4,346 | 4,772 | 4,400 |
| Receivables | 8,100 | 6,800 | 6,199 | 6,219 | 5,537 | 4,076 | 3,343 | 3,865 | 2,745 | 3,092 |
| Inventory | 2,257 | 2,373 | 1,993 | 2,329 | 1,938 | 1,880 | 1,659 | 1,209 | 919 | 895 |
| Net property, plant and equipment | 10,233 | 10,288 | 9,912 | 9,251 | 8,516 | 8,392 | 7,633 | 5,804 | 3,483 | 2,687 |
| Goodwill | 3,496 | 916 | 680 | 663 | 648 | 88.9 | 88.9 | 13,897 | 88.9 | 88.9 |
| Other intangible assets | 192 | 272 | 248 | 278 | 292 | 225 | 821 | 7,844 | 55.1 | 63.0 |
| Long-term investments | 23,465 | 26,337 | 25,181 | 25,230 | 25,169 | 13,857 | 2,020 | 1,070 | 1,779 | 1,412 |
| Current liabilities | 25,200 | 19,556 | 22,607 | 20,151 | 15,345 | 10,944 | 8,123 | 9,669 | 5,688 | 5,656 |
| Accounts payable | 1,532 | 1,571 | 1,335 | 1,884 | 1,795 | 1,948 | 1,809 | 1,832 | 929 | 827 |
| Long-term debt | 7,584 | 1,997 | 1,074 | 3,934 | 5,213 | 12,363 | 7,885 | 507 | 2,210 | 1,679 |
| Total debt | 16,070 | 9,711 | 12,580 | 13,982 | 12,118 | 14,210 | 7,971 | 555 | 2,223 | 1,693 |
| Total liabilities | 33,924 | 22,634 | 25,435 | 26,121 | 22,814 | 24,791 | 16,953 | 12,231 | 8,324 | 7,706 |
| Total equity (incl. minority) | 42,086 | 42,774 | 38,170 | 37,944 | 37,729 | 22,420 | 20,561 | 37,550 | 12,611 | 10,678 |
| Retained earnings | 24,953 | 25,281 | 23,649 | 28,358 | 27,215 | 13,603 | 11,950 | 16,811 | 8,475 | 6,754 |
| Minority interest | 11,415 | 10,813 | 7,695 | 8,197 | 7,438 | 5,672 | 5,612 | 8,337 | 3,402 | 2,773 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 83,208 | 76,010 | 74,894 | 65,408 | 66,704 | 63,605 | 65,641 | 64,064 | 64,934 | 60,543 |
| Current assets | 44,039 | 34,465 | 33,820 | 24,685 | 25,222 | 23,806 | 26,977 | 25,935 | 25,198 | 23,503 |
| Cash and equivalents | 14,882 | 12,181 | 11,104 | 9,570 | 8,549 | 9,452 | 11,577 | 12,066 | 7,768 | 10,569 |
| Short-term investments | — | 415 | 8,719 | 221 | — | 1,553 | 160 | — | — | 570 |
| Receivables | 11,142 | 8,100 | 8,446 | 6,800 | 7,361 | 6,199 | 7,189 | 6,219 | 5,355 | 5,537 |
| Inventory | 1,968 | 2,257 | 2,104 | 2,373 | 1,837 | 1,993 | 2,018 | 2,329 | 2,137 | 1,938 |
| Net property, plant and equipment | 10,071 | 10,233 | 10,054 | 10,288 | 9,678 | 9,912 | 9,584 | 9,251 | 8,772 | 8,516 |
| Goodwill | 4,353 | 3,496 | 912 | 916 | 701 | 680 | 812 | 663 | 643 | 648 |
| Other intangible assets | 3,755 | 192 | 2,208 | 272 | 2,422 | 248 | 2,130 | 278 | 1,214 | 292 |
| Long-term investments | 20,155 | 23,465 | 26,927 | 26,337 | 27,410 | 25,181 | 24,263 | 25,230 | 27,435 | 25,169 |
| Current liabilities | 27,024 | 25,200 | 24,851 | 19,556 | 21,949 | 22,607 | 26,865 | 20,151 | 16,266 | 15,345 |
| Accounts payable | 2,166 | 1,532 | 2,820 | 1,571 | 2,191 | 1,335 | 2,167 | 1,884 | 3,076 | 1,795 |
| Long-term debt | 8,430 | 7,584 | 2,999 | 1,997 | 1,010 | 1,074 | 702 | 3,934 | 7,543 | 5,213 |
| Total debt | 17,171 | 16,070 | 11,956 | 9,711 | 9,677 | 12,580 | 11,554 | 13,982 | 12,017 | 12,118 |
| Total liabilities | 36,963 | 33,924 | 29,117 | 22,634 | 24,582 | 25,435 | 29,182 | 26,121 | 26,190 | 22,814 |
| Total equity (incl. minority) | 46,245 | 42,086 | 45,778 | 42,774 | 42,122 | 38,170 | 36,459 | 37,944 | 38,745 | 37,729 |
| Retained earnings | 27,606 | 24,953 | 28,019 | 25,281 | 31,847 | 23,649 | 28,641 | 28,358 | 28,544 | 27,215 |
| Minority interest | 13,677 | 11,415 | 12,404 | 10,813 | 9,277 | 7,695 | 6,470 | 8,197 | 8,530 | 7,438 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 9,292 | 6,615 | 6,066 | 6,265 | 5,366 | 5,325 | 5,325 | 5,094 | 3,733 | 2,995 |
| Depreciation and amortization | 1,041 | 1,175 | 1,004 | 968 | 923 | 1,637 | 1,405 | 1,160 | 340 | 312 |
| Capital expenditure | -1,239 | -960 | -1,068 | -1,243 | -1,714 | -1,424 | -1,449 | -1,550 | -1,058 | -779 |
| Investing cash flow | -12,414 | -1,709 | -757 | -4,071 | -2,516 | -7,846 | -3,824 | -616 | -1,627 | -2,234 |
| Financing cash flow | 4,157 | -6,315 | -6,549 | -3,186 | -3,225 | 2,233 | 2,801 | -2,178 | -1,698 | 567 |
| Dividends paid | -1,503 | -1,846 | -633 | -1,268 | -938 | -1,187 | -820 | -710 | -450 | -376 |
| Share repurchases | -110 | -1,252 | -396 | -868 | -333 | -195 | -32.1 | -604 | — | — |
| Debt issued | 13,601 | 11,696 | 12,194 | 9,753 | 1,406 | 7,150 | 8,395 | 398 | 692 | 2,649 |
| Debt repaid | -7,257 | -14,475 | -13,948 | -8,790 | -2,908 | -1,809 | -3,230 | -93.8 | -790 | -1,047 |
| Effect of exchange rates | 118 | 136 | 90.5 | 47.3 | -650 | 280 | 95.1 | 242 | -218 | 53.1 |
| Net change in cash | 1,153 | -1,274 | -1,150 | -945 | -1,025 | -7.0 | 4,396 | 2,543 | 190 | 1,381 |
| Free cash flow | 8,053 | 5,655 | 4,998 | 5,022 | 3,652 | — | — | — | — | — |
| Levered free cash flow | 6,601 | 3,905 | 3,006 | 2,991 | -197 | 3,669 | 3,111 | 2,204 | 2,156 | 442 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4,319 | 6,131 | 3,160 | — | 3,078 | — | 2,671 | — | 3,949 | 3,031 |
| Depreciation and amortization | 546 | 466 | 576 | — | 510 | — | 631 | — | 409 | 510 |
| Capital expenditure | -299 | -968 | -271 | — | -407 | — | -754 | — | -627 | -1,129 |
| Investing cash flow | 1,974 | -5,125 | -7,289 | — | -2,041 | — | -4,075 | — | -5,990 | 1,540 |
| Financing cash flow | -1,492 | 2,580 | 1,577 | — | -4,099 | — | -4,042 | — | -1,461 | -2,464 |
| Dividends paid | — | -1,503 | — | — | — | — | — | — | — | -938 |
| Share repurchases | -331 | -0.0 | -110 | — | -362 | — | -236 | — | -809 | -333 |
| Debt issued | 7,289 | 8,732 | 4,868 | — | 6,712 | — | 10,926 | — | 7,719 | 859 |
| Debt repaid | -6,189 | -4,624 | -2,633 | — | -9,396 | — | -13,869 | — | -8,121 | -2,102 |
| Effect of exchange rates | -61.2 | 148 | -29.6 | — | 26.3 | — | 84.8 | — | -32.9 | -536 |
| Net change in cash | 4,739 | 3,734 | -2,581 | — | -3,036 | — | -5,361 | — | -3,534 | 1,571 |
| Free cash flow | 4,020 | 5,163 | 2,890 | — | 2,671 | — | 1,917 | — | 3,322 | 1,902 |
| Levered free cash flow | 961 | 4,321 | 2,339 | — | 1,994 | — | 5,357 | — | 3,391 | 4,909 |
Financial statements of similar companies
Companies in the group: same industry, similar size
